Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Donor Plasma Mitochondrial DNA Predicts Post-Transplant Renal Allograft Outcomes
F. Han,¹ S. Wan,² N. Chen,² L. Zheng,³ N. Zhang,⁴ Q. Sun,¹ H. Li,¹ Z. Huang,¹ L. Hong,¹ Q. Sun.¹
¹Kidney Transplantation, Sun Yat-sen University, Guangzhou, China; ²Laboratory of Cancer Biomarkers and Liquid Biopsy, Henan University, Henan, China; ³Department of Medical Statistics and Epidemiology, Sun Yat-sen University, Guangzhou, China; ⁴Department of Pathology, Sun Yat-sen University, Sun Yat-sen, China.
The lack of an accurate biomarker makes it difficult to determine whether an organ is acceptable for transplantation. Mitochondrial DNA (mtDNA) correlates with tissue damage…
2018 American Transplant Congress
Effect of De Novo Use of Everolimus with Reduced Calcineurin Inhibitor versus Standard Mycophenolic Acid-Based Regimen on Wound Healing Events in Kidney Transplant Recipients from TRANSFORM Study
M. Henry, F. Citterio, M. Kim, D. Kim, P. Bernhardt, A. Gupta, Y. Watarai.
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Anti-proliferative properties of mammalian target of rapamycin inhibitors (mTORi) may affect the wound healing process and there are some reservations about including mTORi into…
2018 American Transplant Congress
Long Term Outcomes of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant
Y. Kassis,¹ S. Park,¹ A. Shetty,¹ J. Leventhal,¹ V. Mas,² L. Gallon.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²Department of Surgery, University of Virginia, Charlottesville, VA.
Tacrolimus (Tac) is the most effective immunosuppressive agent to prevent acute allograft rejection. However, long-term transplant (Tx) outcomes are limited, at least in part, by…
2018 American Transplant Congress
Opting out and Offers of 'Alibis' for Potential Living Kidney Donors in the US
R. Iskander,¹ S. Kulkarni,² C. Thiessen.²
¹McMaster University, Hamilton, ON, Canada; ²Yale University School of Medicine, New Haven, CT.
Purpose: To delineate rates of and reasons for opting out of living kidney donation, to determine if and how transplant centers offer alibis, to assess…
2018 American Transplant Congress
The New Crescentic Incision: A Good Option for Donor Nephrectomy
M. Haberal,¹ M. Kirnap,¹ A. Akdur,¹ E. Ayvazoglu Soy,¹ S. Yildirim,¹ G. Moray,¹ Z. Kayhan,² A. Torgay.²
¹Transplantation, Baskent University, Ankara, Turkey; ²Anesthesiology, Baskent University, Ankara, Turkey.
Introduction: Living kidney donation helps to avoid or reduce the time period of dialysis and time spent on waiting lists for patients requiring a new…
2018 American Transplant Congress
The Impact of Lymphocele Formation after Kidney Transplantation on De Novo Donor Specific Antibody Formation
L. Lehner, A. Hohberger, F. Halleck, E. Schrezenmeier, K. Budde, O. Staeck, D. Khadzhynov.
Dept. of Nephrology and Medical Intensive Care, Charité Universtitätsmedizin Berlin, Berlin, Germany.
Introduction: Lymphocele formation is a common complication after kidney transplantation and has been linked to rejection episodes. However, long-term outcome data are scarce and the…
2018 American Transplant Congress
Prevalence, Risk Factors and Impact of BK Viremia on Kidney Transplantation: Single Center Experience
W. Hassan, A. El-Husseini, B. Suleiman, K. Wang, M. Yaseen, A. Maibam, A. Karim, A. Hines, A. Castellanos, V. Cornea, X. Mei, R. Gedaly, T. Waid.
Nephrology, University of Kentucky, Lexington, KY.
Introduction: BK viremia (BKV) is an emerging problem in renal transplantation. The risk factors and the impact of BKV on renal allograft and patient survival…
2018 American Transplant Congress
Participation in Paid Work across the Transplant Trajectory from the Perspective of End-Stage-Kidney-Disease Patients
K. Gaudet, M. Achille.
Psychology, University of Montreal, Montreal, QC, Canada.
Purpose: To explore end-stage-kidney-disease patients' experiences of labour participation, from the kidney failure diagnosis to the post-transplant recovery period.Methods: A qualitative research design was adopted.…
2018 American Transplant Congress
Effect of Conversion to CTLA4Ig Treatment on Tacrolimus-Induced Diabetic Rats
J. Il,¹ L. Jin,¹ K. Luo,¹ S. Lim,¹ Y. Shin,¹ E. Ko,^1,2 B. Chung,^1,2 C. Yang.^1,2
¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; ²Transplant Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Background: The effect of conversion to cytotoxic T-lymphocyte-associated protein 4 immunoglobulin (CTLA4Ig) treatment on tacrolimus (TAC)-induced renal dysfunction is well known, but its effect on…
2018 American Transplant Congress
Cognitive Impairment and Graft Loss in Kidney Transplant Recipients
A. Thomas,¹ J. Ruck,¹ A. Shaffer,¹ C. Haugen,¹ H. Ying,¹ F. Warsame,¹ N. Chu,¹ M. Carlson,¹ A. Gross,¹ S. Norman,² D. Segev,¹ M. McAdams-DeMarco.¹
¹JHU, Baltimore; ²University of Michigan, Ann Arbor.
Cognitive impairment is common in end-stage renal disease patients and impedes adherence to complex treatment regimens. Given the complexities of post-transplant immunosuppression, we hypothesized that…